By the end of the trial, the highly significant difference in tumour progression rates was not mirrored in the overall survival measure between the two treatment groups.
← all excerpts
Gaining power and precision by using model-based weights in the analysis of late stage cancer trials with substantial treatment switching.
1
—
—